(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    Int J Stem Cells, 2018, 11(1):131-140. (+)-JQ1 purchased from Selleck.

  • JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

    immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

  • Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  MmrtR4VtdCCYaXHibYxqfHliQYPzZZk> MnTJNlUxNzVyMD:xNFAxKG6P M{PhTFI1NzR6L{eyJIg> MljTSG1UVw>? NXTpXlE3cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? NUXCcGkyOjZ5MEe4PFE>
BCPAP M2PSPWNmdGxiVnnhZoltcXS7IFHzd4F6 MlzTNlUxNzVyMD:xNFAxKG6P NG\FTIQzPC92OD:3NkBp Mn;xSG1UVw>? MVLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M3ntfVI3PzB5OEix
K1  NFHz[WhE\WyuIFP5Z4xmKEG|c3H5 MYOyOVAwPTByL{GwNFAhdk1? M1XmXlczKGh? NIrWXlFFVVOR MX;hdpJme3S|IHPlcIwh[3mlbHWgZZQhTzBxR{GgdIhie2V? MWSyOlcxPzh6MR?=
BCPAP M3niRWNmdGxiQ4njcIUhSXO|YYm= M4nuT|I2OC93MECvNVAxOCCwTR?= NVy5PVZ3PzJiaB?= M3v2RmROW09? M1i3U4FzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= M33abVI3PzB5OEix
Hep3B NFfuVIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPrWoJrOC1zMDFOwG0> M2XEV|Uh\A>? NGPhUXJFVVOR MYnJR|UxRTBwMEig{txO M4KzRlI3PTd3MU[3
HCCLM3 MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKwMVExKM7:TR?= MmO5OUBl NYr4TnlwTE2VTx?= MUjJR|UxRTBwMUSg{txO MkDDNlY2PzVzNke=
HuH7 M37PO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\5RVAuOTBizszN MlPKOUBl Mlm1SG1UVw>? MYjJR|UxRTBwMkGg{txO M3TyeVI3PTd3MU[3
HepG2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrNO5oxNTFyIN88US=> M2n0cFUh\A>? M2i1eWROW09? MoToTWM2OD1yLkO0JO69VQ>? NU\zSZhkOjZ3N{WxOlc>
SMMC7721 M1Tacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu2PHUxNTFyIN88US=> MW[1JIQ> MoP3SG1UVw>? MlfuTWM2OD1yLkSxJO69VQ>? M1ixSFI3PTd3MU[3
BEL7402 NV3KTod[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LJSFAuOTBizszN NV7kVI5[PSCm NVvKPGFnTE2VTx?= NX7GOndsUUN3ME2wMlQ4KM7:TR?= NIi0SG0zPjV5NUG2Oy=>
MHCC97H MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGwMVExKM7:TR?= NVq0cXRnPSCm NHTMZVNFVVOR NHnib3lKSzVyPUCuOFEh|ryP M1jPclI3PTd3MU[3
Hep3B NVzhUG9uS2WubDDDfYNt\SCDc4PhfS=> NYWwbI9[OC5zL{CuOU8zNjVizszN MVy0PEBp M{PB[WROW09? NEWyWZlt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iCKQ1OgZ4VtdHNiaX6gd5VjNUdzIIDoZZNmyqB? MX2yOlU4PTF4Nx?=
HCCLM3 MVjD[YxtKEO7Y3zlJGF{e2G7 NVXn[WhkOC5zL{CuOU8zNjVizszN MojROFghcA>? MmXESG1UVw>? NXPI[FRidGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZiSFPDJINmdGy|IHnuJJN2[i2JMTDwbIF{\cLi NUfib5BLOjZ3N{WxOlc>
Hep3B MV\BdI9xfG:|aYOgRZN{[Xl? MkXSNE4yNzBwNT:yMlUh|ryP NHvS[W01QCCq M1TVdWROW09? NVHnSnVD[WO2aY\heIV{KGOjc4Dhd4UuOyCjbnSgZ4F{eGG|ZT25JIV5eHKnc4Ppc44h[W6mIHnu[JVk\WRiUFHSVEBkdGWjdnHn[UBieyC5ZXzsJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bTDmdo9uKG2rdH;jbI9v\HKrYR?= NX\uXXdLOjZ3N{WxOlc>
HCCLM3 NHS1WHRCeG:ydH;zbZMhSXO|YYm= M33G[|AvOS9yLkWvNk42KM7:TR?= NIPNWYE1QCCq MlXUSG1UVw>? Mn30ZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>? NFfBcFQzPjV5NUG2Oy=>
A549 NFr2SnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP2eYUxNjFvMUCg{txO MXm3NkBp NG\uc3NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVPYe5RrOjZ2MUWyNlU>
H157 NV;NelhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzUW4IxNjFvMUCg{txO M4T2SlczKGh? NIXR[GRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHu4U4QzPjRzNUKyOS=>
H1299 MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPDZlExNjFvMUCg{txO Mk\vO|IhcA>? MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGPlU3IzPjRzNUKyOS=>
A549 MkPsSpVv[3Srb36gRZN{[Xl? M3XsVFEwOi53L{Wg{txO NHXBd4EyOiCq NGDXWYTDqHenYXvsfUBl\WO{ZXHz[YQhSmOuLUKgcIV3\Wy| MVeyOlQyPTJ{NR?=
H1299 NFHWfJRHfW6ldHnvckBCe3OjeR?= M4\KV|EwOi53L{Wg{txO NGPTW5UyOiCq M3LZduKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN? Mn;ONlY1OTV{MkW=
H157 MoPJSpVv[3Srb36gRZN{[Xl? M2fzRlEwOi53L{Wg{txO MnrLNVIhcA>? MUTk[YNz\WG|ZXSgSHI1KGW6cILld5Nqd25? MljrNlY1OTV{MkW=
H1299 NXK5[ZViTnWwY4Tpc44hSXO|YYm= NVjNeld1OS9{LkWvOUDPxE1? MVuxNkBp NW[4[5l5\GWlcnXhd4VlKESUNDDlfJBz\XO|aX;u MofLNlY1OTV{MkW=
C8161 M4rWPGNmdGxiVnnhZoltcXS7IFHzd4F6 MnixNE0zKM7:TR?= NFjXb3g1KGR? NHHiRplFVVOR M4PMNYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MkXMNlY{QTd{MkO=
Mel285 MnHPR4VtdCCYaXHibYxqfHliQYPzZZk> MWCwMVIh|ryP MkDxOEBl MnX2SG1UVw>? NXrkeWlp\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MYKyOlM6PzJ{Mx?=
Mel290 MkHUR4VtdCCYaXHibYxqfHliQYPzZZk> MX:wMVIh|ryP MknSOEBl MmTxSG1UVw>? NWfhPXYz\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MX6yOlM6PzJ{Mx?=
92.1 M3Pue2NmdGxiVnnhZoltcXS7IFHzd4F6 NVvhcIgxOC1{IN88US=> MXy0JIQ> MmTXSG1UVw>? MWTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn3JNlY{QTd{MkO=
Omm1.3 MnPFR4VtdCCYaXHibYxqfHliQYPzZZk> MYKwMVIh|ryP M2T4bFQh\A>? MoH5SG1UVw>? NWexT2NJ\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3rSVFI3Ozl5MkKz
Mel202 NIn6OVlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHXMSJMxNTJizszN M4XubVQh\A>? MYXEUXNQ MonX[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUiwbXJOOjZ|OUeyNlM>
Mel270 NWHmTG1kS2WubDDWbYFjcWyrdImgRZN{[Xl? MUSwMVIh|ryP M1r1S|Qh\A>? M3q0N2ROW09? M2DDSoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NX\mfYZ[OjZ|OUeyNlM>
Omm1 MlLXR4VtdCCYaXHibYxqfHliQYPzZZk> MXOwMVIh|ryP M322NVQh\A>? MYjEUXNQ M{Sze4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmPMNlY{QTd{MkO=
92.1 NXTaS5Z7SXCxcITvd4l{KEG|c3H5 Mli3OVAxKG6P MUK0PEBp M3:xVGROW09? NFPvfINqdmS3Y3XzJIFxd3C2b4Ppdy=> NXHwTVhROjZ|OUeyNlM>
Omm1.3 Ml21RZBweHSxc3nzJGF{e2G7 M3f3PVUxOCCwTR?= MVu0PEBp NFvuZ5hFVVOR MmDxbY5lfWOnczDhdI9xfG:|aYO= M3fiRVI3Ozl5MkKz
92.1 NIntfYlE\WyuIFP5Z4xmKEG|c3H5 MVO1NFAhdk1? NHryb|UzPC92OD:3NkBp MlXBSG1UVw>? M4HsTolv\HWlZYOgeIhmKGOnbHygZYNkfW23bHH0bY9vKGG2IIP1Zk1IOcLi NX\5dY82OjZ|OUeyNlM>
Omm1.3 M4f2[WNmdGxiQ4njcIUhSXO|YYm= NX7OdmRrPTByIH7N MXmyOE81QC95MjDo MWfEUXNQ NUXHXVJQcW6mdXPld{B1cGViY3XscEBi[2O3bYXsZZRqd25iYYSgd5VjNUdzwrC= NUHGPINjOjZ|OUeyNlM>
A549 NV7ZeW1qTnWwY4Tpc44hSXO|YYm= MYGxNFAwPDByL{GwNFAhdk1? M{DVVFI1KGh? NEjJcWR2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz MWqyOlIyOjF7OR?=
MCF-7 NHjtcFBHfW6ldHnvckBCe3OjeR?= NGO5UYEyODBxNECwM|ExODBibl2= MV6yOEBp NULhTGZofXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= NU\YWYlGOjZ{MUKxPVk>
HEK293 MXnGeY5kfGmxbjDBd5NigQ>? NELLT5cyODBxNECwM|ExODBibl2= NGjQUYQzPCCq M33oU5VxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? M2XTOVI3OjF{MUm5
858 NYjnOnN4S2WubDDWbYFjcWyrdImgRZN{[Xl? M4L6TFAuOSEQvF2= MVG1JIQ> MWDEUXNQ MXzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlPyNlYzODZ|M{O=
DDR2L63V MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV:wMVEh|ryP NX24ZnJmPSCm Mkj0SG1UVw>? MWjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUWyOlIxPjN|Mx?=
BE(2)-C MnTXR4VtdCCYaXHibYxqfHliQYPzZZk> MV2xJO69VQ>? M1XMfFEuPCCm M4rn[IRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NUjjZVdvOjZyNke0OlQ>
IMR-32 NGXTToJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1;6NlEh|ryP NUf1cWNNOS12IHS= NHzrV4Fl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MlLsNlYxPjd2NkS=
JF MknwR4VtdCCYaXHibYxqfHliQYPzZZk> NH7XbZgyKM7:TR?= M3;sSlEuPCCm NIDLV4Jl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? M4LPblI3ODZ5NE[0
BE(2)-M17 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUfNVWR6OSEQvF2= NF[z[28yNTRiZB?= NV2wWnBw\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? Mmr4NlYxPjd2NkS=
SK-N-SH MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYCxJO69VQ>? NWm2SIpUOS12IHS= M4DGR4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 M2LGeFI3ODZ5NE[0
SK-N-DZ  Mmm0R4VtdCCYaXHibYxqfHliQYPzZZk> NYnHZ2dYOSEQvF2= MWmxMVQh\A>? M3jaVoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MoXkNlYxPjd2NkS=
HMC-1.1  MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjRPVI2NTVyMECgcm0> MmXUOFghcA>? MX3EUXNQ NHzmVXdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MYeyOlA2PTNyMx?=
HMC-1.2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi1dmQ6PS13MECwJI5O NGXUNZI1QCCq MUPEUXNQ M37vWYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2PzflI3ODV3M{Cz
ROSA KIT WT  M3;CV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGG4WGc2NTVyMECgcm0> M3roWVQ5KGh? MVXEUXNQ MojObY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NEfyWVAzPjB3NUOwNy=>
ROSA KIT D816V Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P0WVUuPTByMDDuUS=> NHLLSok1QCCq MkPmSG1UVw>? NE[2PW5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4ruNlI3ODV3M{Cz
HMC-1.1  M1ezR2Fxd3C2b4Ppd{BCe3OjeR?= NInudVczODBvNUCwNEBvVQ>? NIWyXZo1QCCq MV\EUXNQ NIjUNIJqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MWWyOlA2PTNyMx?=
HMC-1.2 NV2z[3lwSXCxcITvd4l{KEG|c3H5 MVmyNFAuPTByMDDuUS=> NV\4XVliPDhiaB?= MmrESG1UVw>? NHj2eGZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MVmyOlA2PTNyMx?=
ROSA KIT WT  MYnBdI9xfG:|aYOgRZN{[Xl? NVH1d5AxOjByLUWwNFAhdk1? NXnXNlhXPDhiaB?= M4fpUGROW09? NI\uN29qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mmn4NlYxPTV|MEO=
ROSA KIT D816V MlnZRZBweHSxc3nzJGF{e2G7 M3T4W|IxOC13MECwJI5O M{e4flQ5KGh? M2TGb2ROW09? MXTpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVqyOlA2PTNyMx?=
494H MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIm0c4c4OiCq MYrEUXNQ NXy4Z5NRUUN3ME2wMlEzOsLzMD6wNFQh|ryP NVPrOYpFOjV7NES1OlY>
493H NWDmVI1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPLZZQ4OiCq M1vHcGROW09? Mln0TWM2OD1yLkC0O:KyOC5yMEmg{txO MVKyOVk1PDV4Nh?=
716H MmPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DYd|czKGh? MYLEUXNQ NGrGOXlKSzVyPUCuNlEzyrFyLkCzOEDPxE1? NUXsZW5NOjV7NES1OlY>
148I M2rWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\oVo04OiCq M{\BbGROW09? M3nGUmlEPTB;MD6yPFTDuTBwMEO1JO69VQ>? MUGyOVk1PDV4Nh?=
98Sc NHnLTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnhWVM4OiCq MYfEUXNQ M4nqWmlEPTB;MD6xNVXDuTBwMEC0JO69VQ>? MXSyOVk1PDV4Nh?=
89R NIK0[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV63NkBp M1zyXmROW09? M17jW2lEPTB;MD6xNlbDuTBwMECzJO69VQ>? NXPocWJxOjV7NES1OlY>
494L NHG2fmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LJblczKGh? MofRSG1UVw>? Mn;GTWM2OD1yLkOxO:KyOC5yMUKg{txO NUnWT45tOjV7NES1OlY>
493L MoHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7NZW8{PzJiaB?= NXL4SpR1TE2VTx?= MWjJR|UxRTBwMEWwxtExNjBzMTFOwG0> MXuyOVk1PDV4Nh?=
148L NU\OOphTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXLNWNnPzJiaB?= M{Ll[WROW09? MkHHTWM2OD1yLkG0OuKyOC5yMUeg{txO NIq3V4kzPTl2NEW2Oi=>
98L M3fDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXK3NkBp M4DOUmROW09? NYjWOHJyUUN3ME2wMlMxQcLzMD6wNlkh|ryP M4L6bVI2QTR2NU[2
OS17 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\FO|czKGh? M2rtZ2ROW09? MX7JR|UxRTBwMEe5xtExNjByMzFOwG0> MYqyOVk1PDV4Nh?=
OS9 NV;LVpZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYT2NlhvPzJiaB?= M3r2dGROW09? M1jyTWlEPTB;MD60NFbDuTBwMEK4JO69VQ>? Ml\GNlU6PDR3Nk[=
MG63 NV[xZXRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWe3NkBp NVXrb4VQTE2VTx?= MXjJR|UxRTBwMUG0xtExNjB{NTFOwG0> Ml:zNlU6PDR3Nk[=
SAOS2 M1jNcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITY[po4OiCq MlfVSG1UVw>? MmfITWM2OD1yLkKxO:KyOC5yMEOg{txO Mm\kNlU6PDR3Nk[=
U2OS M{\ZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PyXlczKGh? MnXoSG1UVw>? NE\W[oJKSzVyPUCuNVk5yrFyLkCwPEDPxE1? NHrySnkzPTl2NEW2Oi=>
SJSA-1 NGXYbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:3NkBp NX;5N|VSTE2VTx?= NUXlXI5rUUN3ME2wMlExOMLzMD6wNVAh|ryP MX6yOVk1PDV4Nh?=
494H MlizRZBweHSxc3nzJGF{e2G7 M1TuWlAvOjVxMD61M|EvOCEQvF2= NUfjZ5l{OjRiaB?= MYHEUXNQ MXvpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MVSyOVk1PDV4Nh?=
148I Ml7GRZBweHSxc3nzJGF{e2G7 MlTlNE4zPS9yLkWvNU4xKM7:TR?= MXmyOEBp NXjo[XlnTE2VTx?= MUPpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NGXRVpAzPTl2NEW2Oi=>
OS17 NXPyPVJHSXCxcITvd4l{KEG|c3H5 MmS2NE4zPS9yLkWvNU4xKM7:TR?= NFvnXWEzPCCq MUnEUXNQ NYTiVGRicW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li NEK0WWYzPTl2NEW2Oi=>
494H NYK0NIMxSXCxcITvd4l{KEG|c3H5 NX;QOG5sOeLCid88US=> MY[0PEBp M1fONmROW09? MmTubY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 NInKbJEzPTl2NEW2Oi=>
148I M{T5bWFxd3C2b4Ppd{BCe3OjeR?= NIToNm8y6oDLzszN MUG0PEBp NWC0Z|M{TE2VTx?= NFruNWRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJk> NIf5dm0zPTl2NEW2Oi=>
OS17 MUnBdI9xfG:|aYOgRZN{[Xl? MU[x5qCK|ryP NXnLd3lHPDhiaB?= NEnNUXlFVVOR NX3aO211cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 MV:yOVk1PDV4Nh?=
MOLM13 NYX0O5ZRSXCxcITvd4l{KEG|c3H5 NHjjN3gzPTBibl2= NEPsbno1QCCq Ml61SG1UVw>? Mo\EbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk MVeyOVA2Ozh{NR?=
MV4-11  MWrBdI9xfG:|aYOgRZN{[Xl? MkXHNlUxKG6P NWm2UIFKPDhiaB?= NGnvOIhFVVOR NWfzdJNVcW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIH1bZpienSrbnni NHzieWszPTB3M{iyOS=>
MOLM13 NVHOTWhUTnWwY4Tpc44hSXO|YYm= NXfa[GNjOjVyIH7N MlLQNlQhcA>? NUDBVY17TE2VTx?= NVjmO|RO\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ MXiyOVA2Ozh{NR?=
MV4-11  NHzvOnVHfW6ldHnvckBCe3OjeR?= NVXSbYxoOjVyIH7N NGXBWFMzPCCq NXzFXZRjTE2VTx?= NXHkfpZ6\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ NIDMTI0zPTB3M{iyOS=>
MOLM13 NVHkWmN3SXCxcITvd4l{KEG|c3H5 Mnr4NlUxKG6P NHHYZow1QCCq Mkn0SG1UVw>? M3vqRolv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? NV\4RnhLOjVyNUO4NlU>
MV4-11  NWi2RYRjSXCxcITvd4l{KEG|c3H5 M{HMUlI2OCCwTR?= MYi0PEBp NVrLVmN[TE2VTx?= M{jQbIlv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCyb37heIlvcWJ? MU[yOVA2Ozh{NR?=
Hela NHXSemZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmizNE02ODBibl2= M1XCdFczKGh? NHjPS|NFVVOR NYjOPVRt\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MY[yOVAxQTJ7NR?=
HBL-1 NFLT[mxE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnPENE02ODBibl2= NWnGW2U2PzJiaB?= MVjEUXNQ M{fGO4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NX7BUGFHOjVyMEmyPVU>
HLY-1 MorwR4VtdCCYaXHibYxqfHliQYPzZZk> Mnr0NE02ODBibl2= NYm5bmVrPzJiaB?= MV7EUXNQ NYLMNXJt\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3[4WFI2ODB7Mkm1
OCI-Ly3 MoDqR4VtdCCYaXHibYxqfHliQYPzZZk> NFHUcpAxNTVyMDDuUS=> M1PJZVczKGh? MlvNSG1UVw>? NHvDV3Vl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MXSyOVAxQTJ7NR?=
OCI-Ly10 MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M33ySlAuPTByIH7N NHO2b|A4OiCq Mk\vSG1UVw>? M3LlPIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWmyOVAxQTJ7NR?=
SU-DHL-4 NHr0cJRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4q2UlAuPTByIH7N NYHQXWxpPzJiaB?= NGTuc2FFVVOR M4\aXoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NEDC[ZEzPTByOUK5OS=>
SU-DHL-5 M3XGPGNmdGxiVnnhZoltcXS7IFHzd4F6 M1XTXlAuPTByIH7N NIH0TWE4OiCq NEm4cYdFVVOR NUjuZXM3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3LCO|I2ODB7Mkm1
SU-DHL-6 M{HMd2NmdGxiVnnhZoltcXS7IFHzd4F6 M2LmPVAuPTByIH7N Mn3hO|IhcA>? NF;XbZhFVVOR MX7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NU\zW|I3OjVyMEmyPVU>
SU-DHL-10 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYDqVYRxOC13MECgcm0> NFX4Smw4OiCq NEewTZZFVVOR M4fxcYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYGyOVAxQTJ7NR?=
RC-K8 MWDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Ml;tNE02ODBibl2= MkTyO|IhcA>? NFW0fY9FVVOR NXnxbXFV\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NIe3c|kzPTByOUK5OS=>
OCI-Ly8 NVPDcWU5S2WubDDWbYFjcWyrdImgRZN{[Xl? M4HDVlAuPTByIH7N MmfOO|IhcA>? M3HYW2ROW09? MYDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGjQVYYzPTByOUK5OS=>
OCL-Ly18 MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWLoSWljOC13MECgcm0> NIfKV3c4OiCq NITYTFNFVVOR MYTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUSxbG1iOjVyMEmyPVU>
OCI-Ly3 NUf4emJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\HNVczNzJ3MD:1NFAhdk1? MUeyM|ch\A>? NEW2PIdFVVOR MnH0bY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= NXXGRlNCOjVyMEmyPVU>
OCI-Ly8 Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;BNVczNzJ3MD:1NFAhdk1? M3fG[|IwPyCm M13QbGROW09? NVTkbWducW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> NIrVPFYzPTByOUK5OS=>
SU-DHL-4 M2\VNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XwZlE4Oi9{NUCvOVAxKG6P MkG0Nk84KGR? MXvEUXNQ NI\Hbo1qdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg NIDxOYIzPTByOUK5OS=>
SU-DHL-10 NUjEVIk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[xO|IwOjVyL{WwNEBvVQ>? MmDlNk84KGR? MljBSG1UVw>? NWrEbppCcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> M4\LW|I2ODB7Mkm1
OCI-Ly3 M2T5PGFxd3C2b4Ppd{BCe3OjeR?= M3S5VVE4Oi9{NUCgcm0> MXy3[C=> M4m0U2ROW09? MnjCbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 M2TuOVI2ODB7Mkm1
OCI-Ly8 NV;TUpFYSXCxcITvd4l{KEG|c3H5 MWKxO|IwOjVyIH7N MVO3[C=> M1[3VmROW09? M{ThXYlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> MX[yOVAxQTJ7NR?=
SU-DHL-4 NUjnSmJ4SXCxcITvd4l{KEG|c3H5 NVfDO2w2OTd{L{K1NEBvVQ>? NWj4Tpl2P2R? M4CzbWROW09? NILyOI5qdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> NFLBVHQzPTByOUK5OS=>
SU-DHL-10 M1PXR2Fxd3C2b4Ppd{BCe3OjeR?= NUTXeJFMOTd{L{K1NEBvVQ>? M3jET|dl MmG1SG1UVw>? NUn6OZdtcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 NFPXWYQzPTByOUK5OS=>

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID